Life Sciences

Harpoon Therapeutics Files for $75 Million IPO for Cancer Immunotherapy

Edward Kim | |

Developing T cell engagers targeting prostate cancer, ovarian cancer, multiple myeloma and small cell lung cancer (Image: Harpoon Therapeutics)

Opiant Pharmaceuticals Licenses Cannabinoid Overdose Therapy from Sanofi

Edward Kim | |

Opiant is the developer of Narcan for opioid overdoses

Athenex and MAIA Get Approval for Generic Levothyroxine for Hypothyroidism

Edward Kim | |

Hypothyroidism affects 4.6% of the US population aged 12 and older (Image: NIH)

Stemline Gets First FDA Approval for Rare Blood Disease Therapy

Edward Kim | |

Elzonris (tagraxofusp) is the first approved treatment for blastic plasmacytoid dendritic dell neoplasm (BPDCN) and first CD123-targeted therapy (Image: Stemline Therapeutics)

Kalytera Shows Positive Phase 2 Data with CBD in Acute Graft vs Host Disease (GvHD)

Edward Kim | |

Interim data from first cohort shows no patients have developed severe or life-threatening GvHD (Image: Kalytera Therapeutics)

Sutro Biopharma Achieves Another Milestone in Celgene Partnership

Edward Kim | |

Latest $10 million payment from Celgene triggered by development of spray drying technology that advances commercial-scale manufacturing (Image: Sutro Biopharma).

Erasca Announces Launch with $42 Million Series A Round Targeting Cancer

Edward Kim | |

Co-founder Jonathan Lim, MD, was CEO of Ignyta, which was acquired by Roche in February 2018 for $1.7 billion.

Evofem Biosciences Shows Positive Top-Line Phase 3 Results for Hormone-Free Birth Control

Edward Kim | |

Amphora showed 98.7% efficacy in preventing births when used correctly (Image: Evofem Biosciences)

BioCardia Submits FDA Application for New Steerable Cardiovascular Introducer

Edward Kim | |

The AVANCE is designed to introduce cardiovascular catheters into the heart, including via the interatrial septum (Image: BioCardia)

Windtree Shows New Positive Phase 2b Data in Respiratory Distress Syndrome Infants

Edward Kim | |

Data shows reduced incidence and severity of bronchopulmonary dysplasia in preterm Infants with RDS (Image: Windtree Therapeutics)


Symbol Last Price Change % Change






INTERVIEW: CEO Jorge Fernandez - iBlades's Sam Mitchell interview iBlades CEO, Jorge Fernandez